Every material Form 8-K Gossamer Bio, Inc. has filed with the SEC since September 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Gossamer Bio received a Nasdaq letter on September 25, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had completed a 1-for-80 reverse stock split on September 10, 2026, with split-adjusted trading beginning September 11, 2026. The filing shows the listing issue is resolved, but it does not report any change to financial results.
Nasdaq letter dated September 25, 2026 confirms compliance with the minimum bid price rule under Nasdaq Listing Rule 5450(a)(1)
The matter followed a Nasdaq letter received April 8, 2026, after the stock failed to trade at $1.00 or more for 30 consecutive business days
1-for-80 reverse stock split effective September 10, 2026; split-adjusted trading began September 11, 2026
Gossamer Bio said it submitted a New Drug Application to the FDA in September 2026 for seralutinib to treat pulmonary arterial hypertension, its first NDA. The application relies on the Phase 3 PROSERA study as one adequate and well-controlled investigation, supported by the Phase 2 TORREY study. The FDA has not yet decided whether to accept the application for filing, which the company expects could happen later this year.
NDA for seralutinib in PAH submitted to the FDA in September 2026, the company's first NDA
Submission follows a Pre-NDA Type B meeting with the FDA in June 2026 and the FDA's written meeting minutes
FDA will decide whether to accept the NDA for filing after its initial review, which the company anticipates could occur later this year
Gossamer Bio appointed Gregory A. Ciongoli as a Class III director effective September 16, 2026, with a term expiring at the 2027 annual meeting, and also named him to the Audit Committee. The Board determined he is independent under Nasdaq listing rules, and he is a purchaser in the 2026 private placement, so his board seat ties him to securities he has agreed to buy in the company.
Appointed Class III director effective September 16, 2026; initial term expires at the 2027 annual meeting of stockholders
Receives a $40,000 annual cash retainer for Board service and a $7,500 annual cash retainer for Audit Committee service
Purchased initial closing pre-funded warrants in the 2026 PIPE (initial closing August 24, 2026) and agreed to buy second closing and FDA approval warrants
Board determined he is independent under Nasdaq Global Select Market listing requirements
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Gossamer Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →